ntithrombotic Strategy in Non–ST-Segment levation Myocardial Infarction Patients ndergoing Percutaneous Coronary Intervention

ethods Antithrombotic strategies for NSTEMI patients undergoing PCI at 217 ACTION (Acute Coroary Treatment and Intervention Outcomes Network) hospitals from January 1, 2007, to December 1, 2007, (n 11,085) were classified into commonly observed antithrombotic groups: heparin lone (Hep alone; low-molecular-weight heparin or unfractionated heparin), bivalirudin alone (Bival lone), heparin with glycoprotein IIb/IIIa inhibitors (Hep/GPI), and bivalirudin with GPI (Bival/GPI). aseline characteristics are shown across treatment groups. In addition, unadjusted and adjusted ates of in-hospital major bleeding and death are shown.

[1]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[2]  S. Yusuf,et al.  Early versus delayed invasive intervention in acute coronary syndromes. , 2009, The New England journal of medicine.

[3]  Sunil V. Rao,et al.  Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.

[4]  B. Gersh,et al.  Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2009, Journal of the American College of Cardiology.

[5]  A. Kastrati,et al.  Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.

[6]  R. Califf,et al.  Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. , 2008, American heart journal.

[7]  Angelo Branzi,et al.  Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. , 2007, European heart journal.

[8]  J. Ware,et al.  Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. , 2007, JAMA.

[9]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[10]  L. Newby,et al.  Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). , 2007, The American journal of cardiology.

[11]  J. Ware,et al.  Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. , 2007, JAMA.

[12]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[13]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[14]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[15]  E. Topol,et al.  Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. , 2001, American heart journal.

[16]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[17]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.